Multimodal Analgesia Effect on Post Surgical Patient

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

June 24, 2026

Study Completion Date

June 24, 2026

Conditions
Obesity, MorbidSurgeryBariatric Surgery Candidate
Interventions
DRUG

Neurontin

600 mg on-call prior to surgery, post surgery 100 mg liquid q 8-12 hours post surgery with Tylenol every 6 hours

DRUG

Dilaudid Injectable Product

.5-1 mg IV Q3 hours and IV Tylenol 1000mg every 6 hours post surgery transitioning to oral pain control medications (Hycet 7.5/325mg/5 ml, 5-10 ml every 4 hours

DRUG

Marcaine Injectable Product

0.25% local injectable anesthetic agent infiltrated at all laparoscopic incision sites for both groups.

DRUG

Oxycodone Hydrochloride

1 mg/ml oral solution, dosage 5-10mg q4h prn for pain control

DRUG

Hycet 7.5Mg-325Mg/15Ml Solution

Dosage: 10-15ml q4h prn for pain control

DRUG

Zofran Injection

4 mg IV for nausea control while inpatient, prn

DRUG

Scopolamine patch

Topical application patch for nausea control, used with/without Ativan.

DRUG

Ativan

0.5mg IV as needed in conjunction with/without Scopolamine and Zofran for Nausea control

DRUG

Flexeril Oral Product

5 mg orally q8h prn for muscle spasms.

DRUG

Tylenol Suspension

1000 mg q6h PRN for pain control.

Trial Locations (1)

95817

UC Davis Health, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER

NCT04240626 - Multimodal Analgesia Effect on Post Surgical Patient | Biotech Hunter | Biotech Hunter